ALLO
Price
$1.20
Change
-$0.01 (-0.83%)
Updated
Oct 24 closing price
Capitalization
266.26M
4 days until earnings call
Intraday Buy/Sell Signals
ENTA
Price
$10.51
Change
-$0.16 (-1.50%)
Updated
Oct 24 closing price
Capitalization
303.24M
22 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ALLO vs ENTA

Header iconALLO vs ENTA Comparison
Open Charts ALLO vs ENTABanner chart's image
Allogene Therapeutics
Price$1.20
Change-$0.01 (-0.83%)
Volume$1.74M
Capitalization266.26M
Enanta Pharmaceuticals
Price$10.51
Change-$0.16 (-1.50%)
Volume$357.3K
Capitalization303.24M
ALLO vs ENTA Comparison Chart in %
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. ENTA commentary
Oct 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and ENTA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 26, 2025
Stock price -- (ALLO: $1.20 vs. ENTA: $10.51)
Brand notoriety: ALLO and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 57% vs. ENTA: 44%
Market capitalization -- ALLO: $266.26M vs. ENTA: $303.24M
ALLO [@Biotechnology] is valued at $266.26M. ENTA’s [@Biotechnology] market capitalization is $303.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $108.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileENTA’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • ENTA’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTA is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 4 TA indicator(s) are bullish while ENTA’s TA Score has 4 bullish TA indicator(s).

  • ALLO’s TA Score: 4 bullish, 6 bearish.
  • ENTA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а -2.44% price change this week, while ENTA (@Biotechnology) price change was -4.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.97%. For the same industry, the average monthly price growth was +11.13%, and the average quarterly price growth was +63.98%.

Reported Earning Dates

ALLO is expected to report earnings on Oct 30, 2025.

ENTA is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+0.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ENTA($303M) has a higher market cap than ALLO($266M). ENTA YTD gains are higher at: 82.783 vs. ALLO (-43.662). ENTA has higher annual earnings (EBITDA): -82.41M vs. ALLO (-223.22M). ALLO has more cash in the bank: 273M vs. ENTA (204M). ENTA has less debt than ALLO: ENTA (58M) vs ALLO (79.2M). ENTA has higher revenues than ALLO: ENTA (64.8M) vs ALLO (0).
ALLOENTAALLO / ENTA
Capitalization266M303M88%
EBITDA-223.22M-82.41M271%
Gain YTD-43.66282.783-53%
P/E RatioN/AN/A-
Revenue064.8M-
Total Cash273M204M134%
Total Debt79.2M58M137%
FUNDAMENTALS RATINGS
ALLO vs ENTA: Fundamental Ratings
ALLO
ENTA
OUTLOOK RATING
1..100
8184
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
8637
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
5044

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENTA's Valuation (50) in the Biotechnology industry is somewhat better than the same rating for ALLO (96). This means that ENTA’s stock grew somewhat faster than ALLO’s over the last 12 months.

ENTA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that ENTA’s stock grew similarly to ALLO’s over the last 12 months.

ENTA's SMR Rating (98) in the Biotechnology industry is in the same range as ALLO (100). This means that ENTA’s stock grew similarly to ALLO’s over the last 12 months.

ENTA's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for ALLO (86). This means that ENTA’s stock grew somewhat faster than ALLO’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ALLO (100). This means that ENTA’s stock grew significantly faster than ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOENTA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 17 days ago
80%
Bullish Trend 17 days ago
72%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STOHF24.020.95
+4.13%
Equinor ASA
CHFHY11.00N/A
N/A
China Foods Ltd.
KHDHF2.25N/A
N/A
KHD Humboldt Wedag International AG
CRYBF0.04N/A
-1.78%
Dynamite Blockchain Corp.
SBSNY31.41-4.19
-11.77%
VEND MARKETPLACES ASA

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-0.83%
CRSP - ALLO
54%
Loosely correlated
+0.60%
BEAM - ALLO
53%
Loosely correlated
-0.85%
NTLA - ALLO
52%
Loosely correlated
-1.12%
RXRX - ALLO
50%
Loosely correlated
+5.41%
FATE - ALLO
47%
Loosely correlated
+8.55%
More